RALEIGH, N.C., Dec. 1, 2010 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces that two of our Late Phase Services (LPS) leaders will speak at the Late Phase Drug Development World 2010 conference being held 30 November – 3 December 2010 in London, UK. PRA will also host an exhibit at booth 3.
Hani Zaki, PRA's Senior Vice President of LPS and a conference chair, will make the opening remarks on day two of the meeting. His presentation will be followed by LPS Vice President Maria Harrison's discussion on best practices for long-term post-marketing programs. Ms. Harrison's topics will include start-up strategies for building momentum, engagement and collaboration; planning across multiple studies, stakeholders and objectives; and addressing efficiencies and creating opportunities to maximize return on investment.
Additional LPS and other PRA representatives will be available at PRA's booth to discuss our successful approach to late-phase services.
Mr. Zaki, who is responsible for all aspects of PRA's LPS group, has more than 25 years of industry experience in management in the pharmaceutical, CRO and late-phase industries. Ms. Harrison oversees the LPS global operations. She has over 20 years of experience in managing all aspects of drug development in both the pharmaceutical and contract organization industries.
PRA's LPS team supports global and regional post-approval studies utilizing an innovative integrated model combining its international Study Coordinating Center™ with leading technologies and management locations centralized in Horsham, Pennsylvania, and Mannheim, Germany. PRA's highly experienced LPS team assists clients with the post-marketing process by planning and conducting longitudinal and retrospective studies, safety-surveillance studies, large simple trials, registries, and restricted access and risk management programs.
For more information about this conference, navigate to www.praintl.com and click on "Events."
About PRA International
PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 3000 clinical trials through its 38 global offices.
PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.
SOURCE PRA International